
2:00–4:00 pm
2.0 CME CREDITS
![]()
This course will focus on the current rationale for subtyping non-small cell lung cancer (NSCLC) and the appropriate use of immunohistochemistry (IHC). It will clarify what role histology plays in molecular testing and the use of new therapeutic agents. Faculty will explain the latest understanding of acquired resistance to therapy and demonstrate the appropriate use of FNA in rebiopsying patients with known histology for the further delineation of therapy.
You will learn to:
Faculty
Maureen F. Zakowski, MD, FCAP
Cosponsored by ![]()